13F Holdings
中文EN

CAI Caris Life Sciences, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2019410 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY61.5%
TTM net income YoY151.4%
TTM EPS YoY125.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin13.4%
Net margin9.2%
FCF margin2.8%
EBITDA margin15.5%

Returns

ROE17.2%
ROA8.6%
ROIC (approx.)24.3%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets49.1%
Debt / equity0.61x
Current ratio6.71x
Interest coverage3.28x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio1.1%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$812.03M$412.26M$306.13M
R&D expense$101.58M$113.92M$116.88M
SG&A expense$224.97M$169.39M$149.05M
Operating income$45.11M-$257.12M-$319.55M
Interest expense$56.85M$50.02M$31.61M
Pretax income-$68.09M-$281.89M-$341.42M
Income tax$0$0$0
Net income-$68.09M-$281.89M-$341.42M
EBITDA$67.73M-$208.21M-$270.55M
EPS (basic)-3.22-10.66-13.24
EPS (diluted)-3.22-10.66-13.24
Weighted avg. shares (diluted)167.21M35.50M34.94M
Balance sheet
Cash & equivalents$796.27M$63.95M—
Short-term investments$2.29M$2.20M—
Receivables$112.14M$88.24M—
Current assets$997.80M$215.73M—
PP&E, net$63.17M$67.82M—
Goodwill$19.34M$19.34M—
Total assets$1.13B$343.73M—
Current liabilities$127.14M$165.42M—
Short-term debt$169,000$60.09M—
Long-term debt$378.82M$319.44M—
Total debt$378.99M$379.53M—
Total liabilities$548.36M$620.92M—
Shareholders' equity$577.31M-$2.50B-$2.14B
Net debt-$417.28M$315.58M—
Shares outstanding282.53M36.50M—
Cash flow statement
Operating cash flow$83.16M-$245.20M-$276.10M
Capital expenditure$16.26M$8.44M$22.32M
Free cash flow$66.89M-$253.64M-$298.42M
Investing cash flow-$16.26M$52.93M$214.77M
Financing cash flow$664.99M$200.29M$10.13M
Depreciation & amortization$22.61M$48.91M$49.00M
Stock-based compensation$70.01M$18.64M$15.24M
Share buybacks$113,000$0$0

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.